Literature DB >> 8661645

Extended intraarterial cisplatin infusion for treatment of gynecologic cancer after alteration of intrapelvic blood flow and implantation of a vascular access device.

T Yamada1, F Ohsugi, T Irie, C Ishii, S Sadaoka, S Tada.   

Abstract

PURPOSE: Twenty-two patients with advanced gynecologic cancer underwent extended intraarterial cisplatin infusion after alteration of the intrapelvic blood flow and implantation of a vascular access device (VAD).
METHODS: To maximize concentrations of cisplatin at the target lesion, the superior and inferior gluteal arteries were embolized with steel coils. The tip of the catheter was inserted into the internal iliac artery; the opposite end of the catheter was connected to the VAD.
RESULTS: Intensive radioisotope accumulation was demonstrated in the anterior division of the pelvis, seen by scintigraphy performed with technetium 99m macroaggregated albumin via the VAD. Local perfusion in the tumor was well seen by ultrasonographic angiography with CO2 microbubbles via the VAD. Continuous consecutive infusion of cisplatin at a rate of 12.5 mg/day via the VAD minimized the toxicity. The overall response rate was 73%. Radical surgery was possible in 16 of the 22 patients after this intraarterial infusion.
CONCLUSION: This method was useful for treating advanced gynecologic cancer without significant toxicity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8661645     DOI: 10.1007/bf02577609

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  11 in total

1.  A phase I trial of continuous infusion cisplatin.

Authors:  M R Posner; L Ferrari; J F Belliveau; F J Cummings; M C Wiemann; A O'Rourke; A B Weitberg; P Calabresi
Journal:  Cancer       Date:  1987-01-01       Impact factor: 6.860

2.  Intraarterial cis-platinum in the management of squamous cell carcinoma of the uterine cervix.

Authors:  J A Carlson; R S Freedman; S Wallace; V P Chuang; J T Wharton; F N Rutledge
Journal:  Gynecol Oncol       Date:  1981-08       Impact factor: 5.482

3.  Treatment of advanced and recurrent squamous carcinoma of the uterine cervix with constant intraarterial infusion of cisplatin.

Authors:  M A Rettenmaier; M F Moran; N F Ramsinghani; M Colman; N A Syed; A Puthawala; F W Jansen; P J DiSaia
Journal:  Cancer       Date:  1988-04-01       Impact factor: 6.860

4.  A phase II study of weekly cisplatin followed by cisplatin and ifosfamide in advanced or recurrent cervical carcinoma.

Authors:  P G Rose; M S Piver; J H Malfetano; T R Baker; R E Hempling; F O Recio
Journal:  Cancer       Date:  1993-04-01       Impact factor: 6.860

5.  Chemotherapy of cervical carcinoma: use of Tc-99m-MAA infusion to predict drug distribution.

Authors:  E E Kim; A G Bledin; J Kavanagh; T P Haynie; V P Chuang
Journal:  Radiology       Date:  1984-03       Impact factor: 11.105

6.  Balloon-occluded arterial infusion therapy in the treatment of primary and recurrent gynecologic malignancies.

Authors:  Y Yamashita; M Takahashi; H Bussaka; Y Korogi; R Saito; K Miyazaki; S Fujisaki; H Okamura
Journal:  Cardiovasc Intervent Radiol       Date:  1989 Jul-Aug       Impact factor: 2.740

7.  Clinical pharmacology of intraarterial cis-diamminedichloroplatinum(II).

Authors:  D J Stewart; R S Benjamin; S Zimmerman; R M Caprioli; S Wallace; V Chuang; D Calvo; M Samuels; J Bonura; T L Loo
Journal:  Cancer Res       Date:  1983-02       Impact factor: 12.701

8.  Prostate cancer: arterial infusion chemotherapy and alteration of intrapelvic blood flow.

Authors:  K Nakamura; S Takashima; H Nakatsuka; Y Onoyama
Journal:  Radiology       Date:  1992-12       Impact factor: 11.105

9.  Cisplatin administered as a continuous 5-day infusion: plasma platinum levels and urine platinum excretion.

Authors:  J F Belliveau; M R Posner; L Ferrari; G W Crabtree; F J Cummings; M C Wiemann; G P O'Leary; H Griffin; M A Phaneuf; A O'Rourke
Journal:  Cancer Treat Rep       Date:  1986-10

10.  Phase I-II trial of percutaneous intra-arterial cis-diamminedichloro platinum (II) for regionally confined malignancy.

Authors:  D B Calvo; Y Z Patt; S Wallace; V P Chuang; R S Benjamin; J D Pritchard; E M Hersh; G P Bodey; G M Mavligit
Journal:  Cancer       Date:  1980-03-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.